A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Hair Made Easi, is one of 24 businesses chosen for the ASCEND Scale Up Programme, led by the GM Business Growth Hub. The programme, delivered in partnership with KPMG, supports ambitious businesses ...

Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...

Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...

Carbon Cell emerged as the winner of the Entrepreneurs' Award in Social Innovation 2025, a distinguished competition hosted by The Company of Entrepreneurs.